Bempedoic acid

Drug Profile

Bempedoic acid

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 04 May 2017 Esperion plans a phase II trial of Hypercholesterolaemia (Adjunctive treatment to PCSK9i) in 2H 2017
  • 20 Mar 2017 Esperion announces intention to submit NDA to US FDA and MAA to the EMA for a cardiovascular indication by 2022 upon successful completion of CLEAR Outcomes
  • 20 Mar 2017 Esperion announces intention to submit NDA to US FDA and MAA to the EMA for Hypercholesterolaemia (Adjunctive treatment) in 1H 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top